Prevention of diabetes in hypertensive patients: Results and implications from the VALUE trial

References

• KingHEpidemiology of glucose intolerance and gestational diabetes in women of childbearing ageDiabetes Care199821Suppl 2B9B139704221
   PubMedGoogle Scholar
• AksnesTAKjeldsenSERostrupMOmvikPHuaTAJuliusSImpact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial populationHypertension20075046747317679652
   PubMed Web of Science ®Google Scholar
• BangaloreSParkarSGrossmanEMesserliFHA meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitusAm J Cardiol20071001254126217920367
   PubMed Web of Science ®Google Scholar
• AlbertiKGZimmetPShawJThe metabolic syndrome – a new worldwide definitionLancet20053661059106216182882
   PubMed Web of Science ®Google Scholar
• CutlerJASorliePDWolzMThomTFieldsLERoccellaEJTrends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988–1994 and 1999–2004Hypertension20085281882718852389
   PubMed Web of Science ®Google Scholar
• BonoraETargherGAlbericheMBonadonnaRCZenereMBSaggianiFMuggeoMIntracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitusJ Clin Endocrinol Metab2001862073207911344209
   PubMedGoogle Scholar
• PatonRCThe natural history of type II diabetesPractical Diabetes198961013
   Google Scholar
• SowersJRInsulin resistance and hypertensionAm J Physiol Heart Circ Physiol2004286H1597H60215072967
   PubMed Web of Science ®Google Scholar
• ManciaGGrassiGZanchettiANew-onset diabetes and antihypertensive drugsJ Hypertens20062431016331092
   PubMed Web of Science ®Google Scholar
• GressTWNietoFJShaharEWoffordMRBrancatiFLHypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities StudyN Engl J Med200034290591210738048
   PubMed Web of Science ®Google Scholar
• MasonJMDickinsonHONicolsonDJCampbellFFordGAWilliamsBThe diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertensionJ Hypertens2005231777178116148594
   PubMed Web of Science ®Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA20022882981299712479763
   PubMed Web of Science ®Google Scholar
• HanssonLLindholmLHNiskanenLEffect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trialLancet199935361161610030325
   PubMed Web of Science ®Google Scholar
• PfefferMASwedbergKGrangerCBEffects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programmeLancet200336275976613678868
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med200034214515310639539
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEWeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trialLancet20043632022203115207952
   PubMed Web of Science ®Google Scholar
• JuliusSWeberMAKjeldsenSEThe Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapyHypertension20064838539116864741
   PubMed Web of Science ®Google Scholar
• McGuireDKWinterfieldJRRytlewskiJAFerranniniEBlocking the renin-angiotensin-aldosterone system to prevent diabetes mellitusDiab Vasc Dis Res20085596618398815
   PubMed Web of Science ®Google Scholar
• Jandeleit-DahmKATikellisCReidCMJohnstonCICooperMEWhy blockade of the renin-angiotensin system reduces the incidence of new-onset diabetesJ Hypertens20052346347315716683
   PubMed Web of Science ®Google Scholar
• AndrawsRBrownDLEffect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials)Am J Cardiol2007991006101217398202
   PubMed Web of Science ®Google Scholar
• WingLMReidCMRyanPA comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderlyN Engl J Med200334858359212584366
   PubMed Web of Science ®Google Scholar
• KjeldsenSEJuliusSManciaGEffects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trialJ Hypertens2006241405141216794491
   PubMed Web of Science ®Google Scholar
• BarzilayJIDavisBRCutlerJAFasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Arch Intern Med20061662191220117101936
   PubMed Web of Science ®Google Scholar
• MacfarlaneDPPatersonKRFisherMCardiovascular drugs as anti-diabetic agents: evidence for the prevention of type 2 diabetesDiabetes Obes Metab20081053354418248492
   PubMed Web of Science ®Google Scholar
• ErikssonJWJanssonPACarlbergBHydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) StudyHypertension2008521030103718981327
   PubMed Web of Science ®Google Scholar
• AbuissaHJonesPGMarsoSPO’KeefeJHJrAngiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trialsJ Am Coll Cardiol20054682182616139131
   PubMed Web of Science ®Google Scholar
• ScheenAJRenin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trialsDiabetes Metab20043048749615671918
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• BoschJYusufSGersteinHCEffect of ramipril on the incidence of diabetesN Engl J Med20063551551156216980380
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet20063681096110516997664
   PubMed Web of Science ®Google Scholar
• WeberMAJuliusSKjeldsenSEBlood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE TrialLancet20043632049205115207957
   PubMed Web of Science ®Google Scholar
• VerdecchiaPAngeliFReboldiGNew-onset diabetes, antihypertensive treatment, and outcomeHypertension20075045946017679646
   PubMed Web of Science ®Google Scholar
• VerdecchiaPReboldiGAngeliFAdverse prognostic significance of new diabetes in treated hypertensive subjectsHypertension20044396396915037557
   PubMed Web of Science ®Google Scholar
• ShiuchiTIwaiMLiHSAngiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic miceHypertension2004431003101015037562
   PubMed Web of Science ®Google Scholar
• ZhouMSSchulmanIHRaijLThe role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertensionAm J Physiol Heart Circ Physiol2009296H833H83919151253
   PubMed Web of Science ®Google Scholar
• KimJAMontagnaniMKohKKQuonMJReciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanismsCirculation20061131888190416618833
   PubMed Web of Science ®Google Scholar
• SteinbergHOBrechtelGJohnsonAFinebergNBaronADInsulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide releaseJ Clin Invest199494117211798083357
   PubMed Web of Science ®Google Scholar
• LeeMHSongHKKoGJAngiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissueKidney Int20087489090018596725
   PubMedGoogle Scholar
• TikellisCCooperMEThomasMCRole of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetesInt J Biochem Cell Biol20063873775116198140
   PubMed Web of Science ®Google Scholar
• SharmaAMJankeJGorzelniakKEngeliSLuftFCAngiotensin blockade prevents type 2 diabetes by formation of fat cellsHypertension20024060961112411451
   PubMed Web of Science ®Google Scholar
• FolliFKahnCRHansenHBouchieJLFeenerEPAngiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels – A potential role for serine phosphorylation in insulin/angiotensin II crosstalkJ Clin Invest1997100215821699410892
   PubMed Web of Science ®Google Scholar
• WeiYSowersJRClarkSELiWFerrarioCMStumpCSAngiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidaseAm J Physiol Endocrinol Metab2008294E345E35118073321
   PubMed Web of Science ®Google Scholar
• GillespieELWhiteCMKardasMLindbergMColemanCIThe impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetesDiabetes Care2005282261226616123505
   PubMed Web of Science ®Google Scholar
• EspositoDLLiYHCamaAQuonMJTyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cellsEndocrinology20011422833284011416002
   PubMed Web of Science ®Google Scholar
• StumpCSHenriksenEJWeiYSowersJRThe metabolic syndrome: role of skeletal muscle metabolismAnn Med20063838940217008303
   PubMed Web of Science ®Google Scholar
• WeiYSowersJRNistalaRAngiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cellsJ Biol Chem2006281351373514616982630
   PubMed Web of Science ®Google Scholar
• AndreozziFLarattaESciacquaAPerticoneFSestiGAngiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser(312) and Ser(616) in human umbilical vein endothelial cellsCirc Res2004941211121815044323
   PubMed Web of Science ®Google Scholar
• TaniyamaYHitomiHShahAAlexanderRWGriendlingKKMechanisms of reactive oxygen species-dependent downregulation of insulin receptor substrate-1 by angiotensin IIArteriosclers Thromb Vasc Biol20052511421147
   PubMed Web of Science ®Google Scholar
• SchulmanIHZhouMSVascular insulin resistance: A potential link between cardiovascular and metabolic diseasesCurr Hypertens Rep200911485519146801
   PubMed Web of Science ®Google Scholar
• HenriksenEJJacobSKinnickTRTeacheyMKKreklerMSelective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker ratsHypertension20013888489011641303
   PubMed Web of Science ®Google Scholar
• HenriksenEJImprovement of insulin sensitivity by antagonism of the renin-angiotensin systemAm J Physiol Regul Integr Comp Physiol2007293R974R98017581838
   PubMedGoogle Scholar
• ZhouMSHernandez SchulmanIPaganoPJJaimesEARaijLReduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressureHypertension200647818616344366
   PubMed Web of Science ®Google Scholar
• SlonigerJASaengsirisuwanVDiehlCJDefective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 ratAm J Physiol Endocrinol Metabol2005288E1074E1081
   PubMed Web of Science ®Google Scholar
• WeiYChenKWhaley-ConnellATStumpCSIbdahJASowersJRSkeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen speciesAm J Physiol Regul Integr Comp Physiol2008294R673R68018094066
   PubMedGoogle Scholar
• LeeMABohmMPaulMBaderMGantenUGantenDPhysiological characterization of the hypertensive transgenic rat TGR(mREN2)27Am J Physiol1996270E919E9298764174
   PubMed Web of Science ®Google Scholar
• BlendeaMCJacobsDStumpCSAbrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpressionAm J Physiol Endocrinol Metabol2005288E353E359
   PubMed Web of Science ®Google Scholar
• LeungPSThe physiology of a local renin-angiotensin system in the pancreasJ Physiol2007580313717218353
   PubMedGoogle Scholar
• TikellisCWookeyPJCandidoRAndrikopoulosSThomasMCCooperMEImproved islet morphology after blockade of the renin-angiotensin system in the ZDF ratDiabetes20045398999715047614
   PubMed Web of Science ®Google Scholar
• KoSHKwonHSKimSRRamipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty ratsBiochem Biophys Res Commun200431611412215003519
   PubMedGoogle Scholar
• DiaoJAllisterEMKoshkinVUCP2 is highly expressed in pancreatic alpha-cells and influences secretion and survivalProc Natl Acad Sci U S A2008105120571206218701716
   PubMedGoogle Scholar
• Van GaalLFMertensILDe BlockCEMechanisms linking obesity with cardiovascular diseaseNature200644487588017167476
   PubMed Web of Science ®Google Scholar
• EngeliSNegrelRSharmaAMPhysiology and pathophysiology of the adipose tissue renin-angiotensin systemHypertension2000351270127710856276
   PubMed Web of Science ®Google Scholar
• LumengCNBodzinJLSaltielARObesity induces a phenotypic switch in adipose tissue macrophage polarizationJ Clin Invest200711717518417200717
   PubMed Web of Science ®Google Scholar
• de AlvaroCTeruelTHernandezRLorenzoMTumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent mannerJ Biol Chem2004279170701707814764603
   PubMed Web of Science ®Google Scholar
• CaiDYuanMFrantzDFLocal and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaBNat Med20051118319015685173
   PubMed Web of Science ®Google Scholar
• FuruhashiMUraNHigashiuraKBlockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertensionHypertension200342768112796280
   PubMed Web of Science ®Google Scholar
• FuruhashiMUraNTakizawaHBlockade of the renin-angiotensin system decreases adipocyte size with improvement in insulin sensitivityJ Hypertens2004221977198215361770
   PubMed Web of Science ®Google Scholar
• AksnesTAKjeldsenSEManciaGThe effect of antihypertensive agents on new-onset diabetes mellitus: time to amend the guidelinesAm J Cardiovasc Drugs2006613914716780387
   PubMedGoogle Scholar